Is Unity Biotechnology (UBX) a Stock to Watch Now That Mizuho Securities Has Begun Covering It?

September 8, 2018 - By Pearl Odom

How Mizuho Securities Currently Rates Unity Biotechnology (UBX)

Mizuho Securities has begun coverage on Unity Biotechnology (UBX) shares recently in analysts note revealed on Friday, 7 September. The financial company has decided to place a “Buy” rating on UBX stock.

Unity Biotechnology, Inc. (NASDAQ:UBX) Ratings Coverage

Among 4 analysts covering Unity Biotechnology (UBX), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Unity Biotechnology has $33 highest and $17 lowest target. $26.75’s average target is 45.46% above currents $18.39 stock price. Unity Biotechnology had 4 analyst reports since May 29, 2018 according to SRatingsIntel.

The stock increased 2.05% or $0.37 during the last trading session, reaching $18.39. About 103,758 shares traded or 10.78% up from the average. Unity Biotechnology, Inc. (UBX) has 0.00% since September 8, 2017 and is . It has underperformed by 12.57% the S&P500.

Analysts await Unity Biotechnology, Inc. (NASDAQ:UBX) to report earnings on November, 8. After $-0.69 actual earnings per share reported by Unity Biotechnology, Inc. for the previous quarter, Wall Street now forecasts -56.52 % EPS growth.

Unity Biotechnology, Inc., a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company has market cap of $778.17 million. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases. It currently has negative earnings. It is also developing programs in pulmonary disorders.

More important recent Unity Biotechnology, Inc. (NASDAQ:UBX) news were published by: which released: “Premarket analyst action – healthcare” on September 07, 2018, also published article titled: “Benzinga’s Top Upgrades, Downgrades For September 7, 2018”, published: “UNITY Biotechnology, Inc. to Participate in the Morgan Stanley 16th Annual Global Healthcare Conference” on September 05, 2018. More interesting news about Unity Biotechnology, Inc. (NASDAQ:UBX) was released by: and their article: “UNITY Biotechnology, Inc. Reports Second Quarter 2018 Financial Results” with publication date: August 09, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.